Jeremy Anthony1,2, Gregory J Esper3, Adriana Ioachimescu4,5. 1. Specialty Care, Atlanta Veterans Affairs Medical Center, Decatur, GA, USA. 2. Division of Endocrinology, Department of Medicine, Emory University, 1365 B Clifton Rd., NE, B6209, Atlanta, GA, 30322, USA. 3. Department of Neurology, Emory University, Atlanta, GA, USA. 4. Division of Endocrinology, Department of Medicine, Emory University, 1365 B Clifton Rd., NE, B6209, Atlanta, GA, 30322, USA. aioachi@emory.edu. 5. Department of Neurosurgery, Emory University, Atlanta, GA, USA. aioachi@emory.edu.
Abstract
PURPOSE: Hypothalamic-pituitary (HP) neurosarcoidosis (NS) accounts for 0.5 % cases of sarcoidosis and 1 % of HP masses. Correlative data on endocrine and neurological outcomes is lacking. METHODS: Retrospective case series and literature review of presentation, treatment and outcome of HP NS. RESULTS: Our series includes 4 men, ages 34-59, followed for a median of 7.3 years (range 1.5-17). All had optic neuropathy, multiple pituitary hormone abnormalities (PHAs) and other organ involvement by sarcoidosis (lung, sino-nasal, brain/spine and facial nerve). Two patients had central diabetes insipidus and one impaired thirst with polydipsia. After treatment with high-dose glucocorticoids, optic neuropathy improved in one case and stabilized in the others. After treatment, HP lesions improved radiologically, but PHAs persisted in all cases. Review of four published series on HP NS in addition to ours yielded 46 patients, age 37 ± 11.8 years, 65 % male. PHAs consisted of anterior hypopituitarism (LH/FSH 88.8 %, TSH 67.4 %, GH 50.0 %, ACTH 48.8 %), hyperprolactinemia (48.8 %) and diabetes insipidus (65.2 %). PHAs were the first sign of disease in 54.3 % patients. Vision problems occurred in 28.3 % patients, but optic neuropathy was not well documented in previous series. Most patients (93.5 %) received high-dose glucocorticoids followed by taper; 50 % also received other immunomodulators, including methotrexate, mycophenolate mofetil, cyclosporine, azathioprine, infliximab and hydrochloroquine. Only 13 % patients showed improvement in PHAs. All-cause mortality was 8.7 %. CONCLUSION: HP NS is a serious disease requiring multidisciplinary treatment and lifelong follow-up. Prospective multicentric studies are needed to determine a more standardized approach to HP NS and outline predictors of disease outcome.
PURPOSE:Hypothalamic-pituitary (HP) neurosarcoidosis (NS) accounts for 0.5 % cases of sarcoidosis and 1 % of HP masses. Correlative data on endocrine and neurological outcomes is lacking. METHODS: Retrospective case series and literature review of presentation, treatment and outcome of HP NS. RESULTS: Our series includes 4 men, ages 34-59, followed for a median of 7.3 years (range 1.5-17). All had optic neuropathy, multiple pituitary hormone abnormalities (PHAs) and other organ involvement by sarcoidosis (lung, sino-nasal, brain/spine and facial nerve). Two patients had central diabetes insipidus and one impaired thirst with polydipsia. After treatment with high-dose glucocorticoids, optic neuropathy improved in one case and stabilized in the others. After treatment, HP lesions improved radiologically, but PHAs persisted in all cases. Review of four published series on HP NS in addition to ours yielded 46 patients, age 37 ± 11.8 years, 65 % male. PHAs consisted of anterior hypopituitarism (LH/FSH 88.8 %, TSH 67.4 %, GH 50.0 %, ACTH 48.8 %), hyperprolactinemia (48.8 %) and diabetes insipidus (65.2 %). PHAs were the first sign of disease in 54.3 % patients. Vision problems occurred in 28.3 % patients, but optic neuropathy was not well documented in previous series. Most patients (93.5 %) received high-dose glucocorticoids followed by taper; 50 % also received other immunomodulators, including methotrexate, mycophenolate mofetil, cyclosporine, azathioprine, infliximab and hydrochloroquine. Only 13 % patients showed improvement in PHAs. All-cause mortality was 8.7 %. CONCLUSION:HP NS is a serious disease requiring multidisciplinary treatment and lifelong follow-up. Prospective multicentric studies are needed to determine a more standardized approach to HP NS and outline predictors of disease outcome.
Entities:
Keywords:
Hypopituitarism; Hypothalamic; Neurosarcoidosis; Pituitary; Vision loss
Authors: Mark E Molitch; David R Clemmons; Saul Malozowski; George R Merriam; Mary Lee Vance Journal: J Clin Endocrinol Metab Date: 2011-06 Impact factor: 5.958
Authors: C Langrand; H Bihan; G Raverot; L Varron; G Androdias; F Borson-Chazot; T Brue; P Cathebras; L Pinede; G Muller; C Broussolle; F Cotton; D Valeyre; P Seve Journal: QJM Date: 2012-06-30
Authors: Jacob J Koczman; Jacinthe Rouleau; Morgan Gaunt; Randy H Kardon; Michael Wall; Andrew G Lee Journal: Semin Ophthalmol Date: 2008 May-Jun Impact factor: 1.975
Authors: Victor Menezo; Aires Lobo; Tun Kuan Yeo; Roland M du Bois; Susan Lightman Journal: Ocul Immunol Inflamm Date: 2009 May-Jun Impact factor: 3.070
Authors: Charlotte Delcourt; Halil Yildiz; Alessandra Camboni; Eric Van den Neste; Véronique Roelants; Alexandra Kozyreff; Jean Paul Thissen; Dominique Maiter; Raluca Maria Furnica Journal: Endocrinol Diabetes Metab Case Rep Date: 2019-09-27
Authors: Arturo Vega-Beyhart; Irene Rocío Medina-Rangel; Andrea Hinojosa-Azaola; Milagros Fernández-Barrio; Ana Sofía Vargas-Castro; Lucía García-Inciarte; Alberto Guzmán-Pérez; Tania Raisha Torres-Victoria; Froylán David Martínez-Sánchez; Mireya Citlali Pérez-Guzmán; José Miguel Hinojosa-Amaya; Andrés León-Suárez; Miguel Angel Gómez-Sámano; Francisco Javier Gómez-Pérez; Daniel Cuevas-Ramos Journal: Clin Rheumatol Date: 2019-08-24 Impact factor: 2.980